Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Acromegaly

Acromegaly

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Acromegaly

35 trials tracked for Acromegaly: 16 in phase 3 or 4 and 5 with published results. The most-cited published study has 82 citations.

35Trials tracked
16Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 6 Phase 3 10 Phase 2 11 Other / NA 8
  1. Phase 3 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed · 82 cited
  2. Phase 4 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed · 79 cited
  3. Phase 3 Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Completed · 57 cited
  4. Phase 3 Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Completed · 41 cited
  5. Phase 3 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed · 3 cited
  6. Phase 4 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed
Show 29 more trials
  1. Phase 4 Effects of Sandostatin LAR® in Acromegaly Completed
  2. Phase 4 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Completed
  3. Phase 4 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed
  4. Phase 4 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed
  5. Phase 3 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed
  6. Phase 3 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed
  7. Phase 3 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed
  8. Phase 3 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed
  9. Phase 3 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed
  10. Phase 3 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed
  11. Phase 2 Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands Completed
  12. Phase 2 Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism Completed
  13. Phase 2 Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. Completed
  14. Phase 2 The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics Completed
  15. Phase 2 A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly Completed
  16. Phase 2 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed
  17. Phase 2 An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly Completed
  18. Phase 2 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) Completed
  19. Phase 2 Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Completed
  20. Phase 2 An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) Completed
  21. Phase 2 Clomiphene Citrate for Treatment of Acromegaly Completed
  22. N/A Acromegaly Treatment Quality of Life Study Completed
  23. N/A Tissue Biomarker for Pegvisomant Action Completed
  24. N/A Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency Completed
  25. N/A Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Completed
  26. N/A Non Interventional Study For Patients Treated With Somavert® Completed
  27. N/A Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly Completed
  28. N/A Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan Completed
  29. N/A Programme of Acromegaly Screening in Patients With Associated Somatic Disorders Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Biomarker-guided therapy using MRI signal and granulation patterns optimizes treatment for acromegaly in Gulf region
Diabetes & Endocrinology Guideline
Biomarker-guided therapy using MRI signal and granulation patterns optimizes treatment for acromegaly in Gulf region Biomarker Guidance May Improve Treatment for Acromegaly Patients
This guideline addresses the management of acromegaly in the Gulf region, focusing on biomarker-guided therapy. It suggests using MRI signal…
New guidelines suggest using MRI signals and tumor patterns to help patients with acromegaly achieve better results from their medication.
Frontiers Oct 13, 2026
Medial cavernous sinus wall resection achieves 85% endocrine remission in functioning pituitary adenomas
Oncology Meta-analysis
Medial cavernous sinus wall resection achieves 85% endocrine remission in functioning pituitary adenomas Surgery Technique Shows High Success for Pituitary Tumor Treatment
This meta-analysis of 493 patients with functioning pituitary adenomas found that medial cavernous sinus wall resection (MCSWR) is associate…
A surgical technique called MCSWR shows high rates of hormone remission and tumor removal for patients with specific pituitary gland tumors.
Sep 18, 2026